Sun L, Handorf EA, Zhou Y, Borghaei H, et al. Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels. Lung Cancer 2024;190:107510.
PMID: 38432028